Deep brain stimulation is a non-invasive neurosurgical treatment involving the placement of an electronic device called a simulator that emits electronic pulses, into the brain. These pulses are delivered to the area where there is the greatest need for stimulation, in the area known as the cerebral cortex. The purpose of this treatment is to increase brain function and improve brain function. This treatment is often used in conjunction with other procedures and is also very successful when it is used alone.
Increasing prevalence of Parkinson’s disease is expected to propel growth of the global deep brain stimulation devices market. For instance, according to the study, ‘Prevalence of Parkinson’s disease (PD) across North America”, published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030.
Increasing number of clinical trials for deep brain stimulation devices is expected to offer lucrative growth opportunities for players in the global deep brain stimulation devices market. For instance, in January 2021, Medtronic plc announced the first enrollment in ADAPT-PD, a trial evaluating the safety and efficacy of adaptive deep brain stimulation in patients with Parkinson's disease. Similarly, in October 2020, Keck Medicine of USC announced to enroll individuals in an international phase 3 clinical trial to examine the safety and effectiveness of deep brain stimulation to treat Alzheimer’s.
Read more @ https://sachinbhombe.blogspot.com/2021/02/augment-growth-of-deep-brain.html
